entertainment -WSS

entertainment

author：leisure time 2025-09-30 16:27:25 - browse：75

Stock exchange — Drew Angerer/Getty Images

Structure Therapeutics reported Monday that its oral GLP-1 drug led to weight loss in two small studies, leading shares to surge in pre-market trading.

In a 12-week Phase 2a study, the daily pill in a capsule formulation led to 6.2% placebo-adjusted weight loss. In a separate 12-week pharmacokinetics study, the company tested a new tablet formulation of the drug, called GSBR-1290, and it led to placebo-adjusted weight loss of up to 6.9%.

Though it’s difficult to compare across different studies, the results appear to approach the levels of weight loss seen at 12 weeks in a separate Phase 2 study of Eli Lilly’s GLP-1 pill called orforglipron. That entire study lasted 36 weeks, but at 12 weeks, participants had about 6%-7% placebo-adjusted weight loss.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： CRISPR technology availability, affordability needs to be expanded

focus

WSS

High breast density mammograms need follow

U.K. officials, researchers try to ease path for bespoke genetic treatments

Asbestos ban is immediate, but health effects will linger for decades

Medicare Advantage insurers pressure Biden for bigger payments

Medicare Advantage insurers pressure Biden for bigger payments

HPV vaccine, cervical cancer study delivers historic results

entertainment

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

BioMarin wins approval for gene therapy to treat hemophilia A

This gene therapy has record $4.25 million price. It's saved children.

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Printout prescription drug information shouldn’t go digital

23andMe had bad news about my health. I wish a person had delivered it

Chinese researcher claims birth of first gene

Moonlake's readout produced a cash windfall. Risks remain

Texas board proposes rules on abortion law emergency exemption

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Readout Newsletter: Illumina, CRISPR, Regeneron

focus

Medicare bonuses could stop drug shortages under Senate plan

Microsoft launches AI tool for clinical documentation through Epic

Medical devices makers are asking for forgiveness, not permission

Prior authorization reform is both possible and imperative

Inaction leaves children at risk from dangerous chemotherapy drug

Medicare drug price lawsuits could be good politics for Biden

focus

hotspot

focus

explore